Payment overview · 2025
General Payments
$264.97
15 reported records · 8 companies
Healthcare provider profile · identity verified
John David Kuruc, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STEUBENVILLE, OH · NPI 1497739171
Verified facts
What the public records show
CMS Open Payments records show John David Kuruc, M.D. received $264.97 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.16 | 34.0% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.55 | 17.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.04 | 11.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.95 | 9.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.25 | 8.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.07 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.99 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.96 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.97 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.16 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.16 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.55 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 98 |
| Omeprazole | Omeprazole | 418 | 104 |
| Gabapentin | Gabapentin | 346 | 51 |
| Lorazepam | Lorazepam | 325 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 302 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 71 |
| Lisinopril | Lisinopril | 288 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 37 |
| Metformin Hcl | Metformin Hcl | 248 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 53 |
| Potassium Chloride | Potassium Chloride | 240 | 61 |
| Furosemide | Furosemide | 238 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 57 |
| Glimepiride | Glimepiride | 218 | 51 |
| Meloxicam | Meloxicam | 215 | 52 |
| Prednisone | Prednisone | 215 | 102 |
| Propranolol Hcl | Propranolol Hcl | 205 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 41 |
| Trazodone Hcl | Trazodone Hcl | 142 | 32 |
| Tramadol Hcl | Tramadol Hcl | 140 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 138 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 47 |
| Paroxetine Hcl | Paroxetine Hcl | 136 | 23 |
| Simvastatin | Simvastatin | 134 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 132 | 15 |
| Sertraline Hcl | Sertraline Hcl | 114 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 111 | 34 |
| Amoxicillin | Amoxicillin | 109 | 76 |
| Carvedilol | Carvedilol | 94 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 92 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 20 |
| Famotidine | Famotidine | 87 | 27 |
| Alprazolam | Alprazolam | 85 | 12 |
| Clonazepam | Clonazepam | 84 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 82 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 16 |
| Losartan Potassium | Losartan Potassium | 80 | 24 |
| Midodrine Hcl | Midodrine Hcl | 80 | 12 |
| Ibuprofen | Ibuprofen | 76 | 20 |
| Cephalexin | Cephalexin | 75 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 30 |
| Mirtazapine | Mirtazapine | 69 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 18 |
| Temazepam | Temazepam | 65 | suppressed |
| Allopurinol | Allopurinol | 61 | 15 |
| Ozempic | Semaglutide | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 11 |
| Diazepam | Diazepam | 57 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 20 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Topiramate | Topiramate | 53 | 15 |
| Lovastatin | Lovastatin | 52 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 16 |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Atenolol | Atenolol | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Naproxen | Naproxen | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 22 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 12 |
| Metolazone | Metolazone | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.97 · 15 records | PFIZER INC. | AJOVY, CAPLYTA, FARXIGA, Kerendia, LOREEV XR, NURTEC ODT, Ozempic, REXULTI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error